The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
|
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
||||||||||||||||
| COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | |||||
| VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | ||||||
| NAME OF ISSUER | TITLE OF CLASS | CUSIP | FIGI | (to the nearest dollar) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
| ARGENX SE | SPONSORED ADR | 04016X101 | 1,826,405 | 3,715 | SH | SOLE | 3,715 | 0 | 0 | |||
| ARROWHEAD PHARMACEUTICALS IN | COM | 04280A100 | 24,410,696 | 908,474 | SH | SOLE | 908,474 | 0 | 0 | |||
| ARVINAS INC | COM | 04335A105 | 9,606,965 | 489,153 | SH | SOLE | 489,153 | 0 | 0 | |||
| BLUEPRINT MEDICINES CORP | COM | 09627Y109 | 19,037,900 | 379,090 | SH | SOLE | 379,090 | 0 | 0 | |||
| C4 THERAPEUTICS INC | COM STK | 12529R107 | 3,702,021 | 1,990,334 | SH | SOLE | 1,990,334 | 0 | 0 | |||
| GENMAB A/S | SPONSORED ADS | 372303206 | 1,839,260 | 52,148 | SH | SOLE | 52,148 | 0 | 0 | |||
| KYMERA THERAPEUTICS INC | COM | 501575104 | 10,872,844 | 782,219 | SH | SOLE | 782,219 | 0 | 0 | |||
| MERUS N V | COM | N5749R100 | 10,141,970 | 430,109 | SH | SOLE | 430,109 | 0 | 0 | |||
| OLEMA PHARMACEUTICALS INC | COM | 68062P106 | 1,097,606 | 88,875 | SH | SOLE | 88,875 | 0 | 0 | |||
| PIERIS PHARMACEUTICALS INC | COM | 720795103 | 984,351 | 3,303,190 | SH | SOLE | 3,303,190 | 0 | 0 | |||
| REGENXBIO INC | COM | 75901B107 | 13,948,599 | 847,424 | SH | SOLE | 847,424 | 0 | 0 | |||
| SILENCE THERAPEUTICS PLC | ADS | 82686Q101 | 12,886,128 | 1,312,233 | SH | SOLE | 1,312,233 | 0 | 0 | |||